Jeffrey Scott Riley - Net Worth and Insider Trading

Jeffrey Scott Riley Net Worth

The estimated net worth of Jeffrey Scott Riley is at least $90,610 dollars as of 2024-04-25. Jeffrey Scott Riley is the Director of Gain Therapeutics Inc and owns about 30,000 shares of Gain Therapeutics Inc (GANX) stock worth over $90,600. Jeffrey Scott Riley is also the CEO and President of Theriva Biologics Inc and owns about 30 shares of Theriva Biologics Inc (TOVX) stock worth over $10. Details can be seen in Jeffrey Scott Riley's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jeffrey Scott Riley has not made any transactions after 2024-03-28 and currently still holds the listed stock(s).

Transaction Summary of Jeffrey Scott Riley

To

Jeffrey Scott Riley Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jeffrey Scott Riley owns 2 companies in total, including Theriva Biologics Inc (TOVX) , and Gain Therapeutics Inc (GANX) .

Click here to see the complete history of Jeffrey Scott Riley’s form 4 insider trades.

Insider Ownership Summary of Jeffrey Scott Riley

Ticker Comapny Transaction Date Type of Owner
TOVX Theriva Biologics Inc 2013-01-07 director
GANX Gain Therapeutics Inc 2024-03-28 director

Jeffrey Scott Riley Latest Holdings Summary

Jeffrey Scott Riley currently owns a total of 2 stocks. Among these stocks, Jeffrey Scott Riley owns 30,000 shares of Gain Therapeutics Inc (GANX) as of March 28, 2024, with a value of $90,600 and a weighting of 99.99%. Jeffrey Scott Riley also owns 30 shares of Theriva Biologics Inc (TOVX) as of January 7, 2013, with a value of $10 and a weighting of 0.01%.

Latest Holdings of Jeffrey Scott Riley

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GANX Gain Therapeutics Inc 2024-03-28 30,000 3.02 90,600
TOVX Theriva Biologics Inc 2013-01-07 30 0.33 10

Holding Weightings of Jeffrey Scott Riley


Jeffrey Scott Riley Form 4 Trading Tracker

According to the SEC Form 4 filings, Jeffrey Scott Riley has made a total of 1 transactions in Gain Therapeutics Inc (GANX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Gain Therapeutics Inc is the acquisition of 30,000 shares on March 28, 2024, which cost Jeffrey Scott Riley around $115,800.

According to the SEC Form 4 filings, Jeffrey Scott Riley has made a total of 0 transactions in Theriva Biologics Inc (TOVX) over the past 5 years. The most-recent trade in Theriva Biologics Inc is the acquisition of 8 shares on January 7, 2013, which cost Jeffrey Scott Riley around $493.

Insider Trading History of Jeffrey Scott Riley

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jeffrey Scott Riley Trading Performance

GuruFocus tracks the stock performance after each of Jeffrey Scott Riley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jeffrey Scott Riley is -5.99%. GuruFocus also compares Jeffrey Scott Riley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jeffrey Scott Riley within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jeffrey Scott Riley's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jeffrey Scott Riley

Average Return

0.75%

Average return per transaction

Outperforming Transactions

33%

1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 10.65 -5.99 -2.33 0.75 -4.97 8.99
Relative Return to S&P 500(%) 7.11 -12.38 -13.33 -24.81 -23.4 -2.27

Jeffrey Scott Riley Ownership Network

Ownership Network List of Jeffrey Scott Riley

No Data

Ownership Network Relation of Jeffrey Scott Riley


Jeffrey Scott Riley Owned Company Details

What does Theriva Biologics Inc do?

Who are the key executives at Theriva Biologics Inc?

Jeffrey Scott Riley is the director of Theriva Biologics Inc. Other key executives at Theriva Biologics Inc include director & CEO and CFO Steven A Shallcross , Chief Operating Officer Francis Tufaro , and 10 percent owner Randal J Kirk .

Theriva Biologics Inc (TOVX) Insider Trades Summary

Over the past 18 months, Jeffrey Scott Riley made no insider transaction in Theriva Biologics Inc (TOVX). Other recent insider transactions involving Theriva Biologics Inc (TOVX) include a net purchase of 240,000 shares made by Steven A Shallcross ,

In summary, during the past 3 months, insiders sold 0 shares of Theriva Biologics Inc (TOVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Theriva Biologics Inc (TOVX) were sold and 240,000 shares were bought by its insiders, resulting in a net purchase of 240,000 shares.

Theriva Biologics Inc (TOVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Theriva Biologics Inc Insider Transactions

No Available Data

Jeffrey Scott Riley Mailing Address

Above is the net worth, insider trading, and ownership report for Jeffrey Scott Riley. You might contact Jeffrey Scott Riley via mailing address: C/o Adeona Pharmaceuticals, Inc, 3930 Varsity Drive, Ann Arbor Mi 48108.

Discussions on Jeffrey Scott Riley

No discussions yet.